Author:
Yavorska Mariya,Tomiciello Miriam,Antonio Sciurti,Cinelli Elisa,Rubino Giovanni,Perrella Armando,Cerase Alfonso,Pastina Pierpaolo,Gravina Giovanni Luca,Arcieri Silvia,Mazzei Maria Antonietta,Migliara Giuseppe,Baccolini Valentina,Marampon Francesco,Minniti Giuseppe,Di Giacomo Anna Maria,Tini Paolo
Abstract
Abstract
Background and aim
Stereotactic radiotherapy (SRT) is an established treatment for melanoma brain metastases (MBM). Recent evidence suggests that perilesional edema volume (PEV) might compromise the delivery and efficacy of radiotherapy to treat BM. This study investigated the association between SRT efficacy and PEV extent in MBM.
Materials and methods
This retrospective study reviewed medical records from January 2020 to September 2023. Patients with up to 5 measurable MBMs, intracranial disease per RANO/iRANO criteria, and on low-dose corticosteroids were included. MRI scans assessed baseline neuroimaging, with PEV analyzed using 3D Slicer. SRT plans were based on MRI-CT fusion, delivering 18–32.5 Gy in 1–5 fractions. Outcomes included intracranial objective response rate (iORR) and survival measures (L-iPFS and OS). Statistical analysis involved decision tree analysis and multivariable logistic regression, adjusting for clinical and treatment variables.
Results
Seventy-two patients with 101 MBM were analyzed, with a mean age of 68.83 years. The iORR was 61.4%, with Complete Response (CR) in 21.8% and Partial Response (PR) in 39.6% of the treated lesions. PEV correlated with KPS, BRAF status, and treatment response. Decision tree analysis identified a PEV cutoff at 0.5 cc, with lower PEVs predicting better responses (AUC = 0.82 sensitivity: 86.7%, specificity:74.4%,). Patients with PEV ≥ 0.5 cc had lower response rates (iORR 44.7% vs. 63.8%, p < 0.001). Median OS was 9.4 months, with L-iPFS of 27 months. PEV significantly impacted survival outcomes.
Conclusions
A more extensive PEV was associated with a less favorable outcome to SRT in MBM.
Funder
Università degli Studi di Siena
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Gritsko VM et al (2009) Brain metastases in melanoma patients: prevalence, management, and outcomes. Cancer. 115(23):5353–5361
2. Dai C et al (2015) Increasing incidence of brain metastases in melanoma patients: implications for treatment strategies. Melanoma Research. 25(2):125–130
3. Lin JJ et al (2021) Brain metastases in melanoma: current management and emerging therapies. Curr Oncol Rep 23(7):1–11
4. Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D (2022) Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol.;40(5):492–516. https://doi.org/10.1200/JCO.21.02314. Epub 2021 Dec 21. Erratum in: J Clin Oncol. 2022;40(12):1392. doi: 10.1200/JCO.22.00593. PMID: 34932393
5. Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, Romano A, Enrici RM (2011) Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 6:48. https://doi.org/10.1186/1748-717X-6-48PMID: 21575163; PMCID: PMC3108308